Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection

By LabMedica International staff writers
Posted on 02 Apr 2026

Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. More...

Standard screening tools such as the Mantoux tuberculin skin test and interferon-gamma release assays cannot indicate infectiousness, and sputum-based diagnostics can miss extrapulmonary disease and are difficult for children to provide. These limitations slow clinical decision-making and contact tracing. New findings now demonstrate a blood test that identifies the active, infectious form of tuberculosis.

Researchers at UC Davis Health’s (Davis, CA, USA) Department of Pathology and Laboratory Medicine developed a TB blood test designed to detect active disease rather than prior exposure. The assay targets antibodies associated specifically with active Mycobacterium tuberculosis infection. By focusing on serologic markers of active disease, the method aims to complement existing screens that primarily reflect immune sensitization.

Operationally, the approach is similar to interferon-gamma release assays in that it measures host immune responses to TB proteins, but it differs by quantifying antibodies linked to active infection. This distinction addresses a central diagnostic gap: current skin and blood tests cannot differentiate active TB from latent infection, even though only active disease is transmissible. The developers state that faster identification of contagious cases can expedite treatment initiation and support infection-control measures.

The test was adapted with a medical technology company for routine clinical use and evaluated in India in a clinical trial conducted from 2019 to 2023 with more than 600 participants. Performance was reported across adult pulmonary TB as well as harder-to-detect presentations in children and extrapulmonary disease. According to the developers, data analysis and a clinical trial report have been submitted to the Indian Council of Medical Research for review.

Plans include potential expansion to neighboring countries following review in India. To support broader clinical deployment, a startup, AppGenex Diagnostics (Mountain View, CA, USA), was co-founded to pursue commercialization activities referenced by the team. The stated goal is to facilitate earlier recognition of contagious cases to help reduce transmission.

“The test performed surprisingly well. In addition to the expected good performance in adult pulmonary TB, which accounts for approximately 60% to 70% of TB infections, it was also able to identify harder-to-detect TB cases in children as well as TB that was in other organs in the body, not in the lungs,” said Imran H. Khan, professor in the UC Davis Department of Pathology and Laboratory Medicine.

“If we can stop the spread of TB by more easily identifying active infections, we can make a significant difference in decreasing global numbers of this devastating disease,” said Khan.

Related Links
UC Davis Health


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Platelet Function Analyzer
PL-12
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.